Please ensure Javascript is enabled for purposes of website accessibility

Here's How the Livongo Acquisition Helps Teladoc

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This healthcare deal was finalized a year ago. Was it the right move?

Telehealth specialist Teladoc Health (TDOC 0.69%) acquired digital health management company Livongo in October 2020. The acquisition brought Livongo's programs for remotely managing conditions like diabetes under Teladoc's umbrella.

In this video from "Beat & Raise" on Motley Fool Live, recorded on Sept. 23, Fool.com contributors Taylor Carmichael and Brian Withers; along with tech, healthcare, and cannabis editor and analyst Olivia Zitkus; discuss the value the Livongo acquisition brings to Teladoc customers and shareholders.

10 stocks we like better than Teladoc Health
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

They just revealed what they believe are the ten best stocks for investors to buy right now... and Teladoc Health wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

 

*Stock Advisor returns as of September 17, 2021

 

 

Taylor Carmichael: I think the Livongo acquisition in retrospect was a really good play for them. I think that's a good way to attach people to their brand, to their name, and just get that continuing use of the system. Because the more people that use it, the more comfortable they are with it, the more it becomes a part of who they are. Just like Amazon, when you have that mindshare. At the time, I was dubious about the acquisition, but now I really do think the Livongo pickup was very smart.

Olivia Zitkus: Livongo is diabetes specialist, so that's a much more in that kind of treatment, you've touchpoint with your patient every single day, many times a day. Which is exactly what we're talking about, Taylor.

Brian Withers: I know Livongo, I was a Livongo shareholder before the acquisition. Diabetes was their first chronic care treatment plan that they're putting together, but they've expanded to other chronic care, and potentially things like smoking cessation and other things that require ongoing services. I think to Taylor's point, Livongo gets them into that chronic care touchpoint where you need ongoing, and the virtual can be a bot or it can be just a record of data at a certain point in time. I think there's potential virtualization where you don't even need to see somebody. [laughs] You take it even one step further.

Taylor Carmichael has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Teladoc Health. The Motley Fool has a disclosure policy.

Stocks Mentioned

Teladoc Health Stock Quote
Teladoc Health
TDOC
$29.20 (0.69%) $0.20

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.